News

Filter

Current filters:

regorafenib

1 to 9 of 17 results

Bayer's regorafenib overcomes resistance in patients with rare sarcoma

22-11-2012

A new targeted drug - German drug major Bayer's (BAYN: DE) regorafenib (trade name Stivarga) - demonstrated…

BayerBiotechnologyOncologyPharmaceuticalregorafenibResearchStivarga

Bayer's Stivarga races to FDA approval on the heels of Zaltrap

07-10-2012

The earlier than expected US Food and Drug Administration approval of German drug major Bayer's (BAYN:…

BayerBiotechnologyMarkets & MarketingNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationSanofiStivargaZaltrap

Early FDA approval for Bayer's Stivarga in advanced colorectal cancer

28-09-2012

Bayer said Stivarga will be ready for distribution as soon as today (September 28 and set a wholesale…

BayerNorth AmericaOncologyPharmaceuticalregorafenibRegulationStivarga

Bayer's regorafenib gets priority review for CRC in Japan

13-09-2012

Germany's Bayer (BAYN: DE) say that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted…

Asia-PacificBayerOncologyPharmaceuticalregorafenibRegulation

Bayer files NDA for regorafenib for the treatment of GIST

31-08-2012

The US subsidiary of Germany's Bayer (BAYB: DE) has submitted a New Drug Application to the US Food and…

BayerBiotechnologyNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulation

More news from ASCO meeting

05-06-2012

More positive late-stage clinical data continued to roll out at the Annual Meeting of the American Society…

AlimtaBayerdabrafenibEli LillyGlaxoSmithKlineOncologyPharmaceuticalregorafenibResearchtrametinib

1 to 9 of 17 results

Back to top